Gene therapy shows lasting promise for halting rare blindness
NCT ID NCT03406104
Summary
This study followed 62 people for five years after they received an experimental gene therapy for a rare genetic eye disease called LHON. The goal was to check the long-term safety of the treatment and see if the vision improvements seen in earlier studies were maintained over time. Researchers tracked participants' vision and quality of life to understand the therapy's lasting effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHNO Les Quinze Vingts
Paris, 75012, France
-
Doheny Eye Center UCLA
Pasadena, California, 91105, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
LMU Klinikum der Universität München / Friedrich-Baur-Institut
Munich, 80336, Germany
-
Moorfields Eye Hospital
London, Greater London, EC1V 2PD, United Kingdom
-
Ospedale Bellaria
Bologna, 40139, Italy
-
Wills Eye Institute
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.